New breakthrough in cancer research promises better immune therapy

A new immune receptor can make T-cell therapy more efficient and may work for more cancers.
A new immune receptor can make T-cell therapy more efficient and may work for more cancers.

In 2017 we reported on an experimental immunotherapy cancer treatment which showed extraordinary results in clinical trials. This type of treatment is known as T-cell cancer therapy.

How exactly does T-cell cancer therapy work?

The field of immunotherapy aims to "supercharge" the body's own immune system, better enabling it to fight cancer.

T-cells are white blood cells that form part of the immune system, detecting and attacking abnormal or foreign cells in the body.

In cancer patients, T-cells normally aren't able to completely rid the body of cancer.

In T-cell therapy, immune cells are engineered to better recognise and fight cancer cells. Researchers extract these cells from blood and “edit” them with gene transfers to produce a potent receptor that can more effectively fight cancer. The cells are then placed back into the patient’s body

While this type of treatment was initially used in patients with an advanced form of leukaemia, a new breakthrough meant that T-cell therapy could be used for many other types of cancer.

What does the new research entail?

According to a news report, in 2020, researchers discovered a new immune cell receptor. This means that T-cell therapy as we know it can work much, much better and fight more cancers as it was only able to recognise a handful of cancers in the past.  

This meant that, because of a T-cell receptor called human leukocyte antigen (HLA), the treatment had to be personalised for every single patient. This is the receptor that enables the cells to detect and fight the cancer.

Usually HLA varies from person to person, but that is where the new discovery could be a breakthrough.

The new study was led by scientists from Cardiff University in the UK who used the CRISPR-Cas9 screening to discover a new type of receptor called MR1. The full study can be found in the journal Nature Immunology.

These receptors do exactly what HLA does, but there is one big difference – the treatment doesn’t differ from person to person, resulting in a much better basis for T-cell therapy.

Too soon to tell, but prospect is exciting

There is, however, one caveat. The research is still very new and was conducted in a lab, which means that positive results first need to be achieved in clinical trials.

Experts remain optimistic and call this discovery an exciting new frontier.

"This research represents a new way of targeting cancer cells, which is really quite exciting, although much more research is needed to understand precisely how it works," says research and policy director Alasdair Rankin from the blood cancer charity Bloodwise, who was not involved in the research

Image credit: iStock

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
The ANC's leadership race is heating up. Who do you think will be elected party president at Nasrec in December?
Please select an option Oops! Something went wrong, please try again later.
Nkosazana Dlamini-Zuma has got it in the bag
7% - 719 votes
I foresee a second term for Cyril Ramaphosa
83% - 8473 votes
Don’t discount a Zweli Mkhize win
10% - 1012 votes
Rand - Dollar
Rand - Pound
Rand - Euro
Rand - Aus dollar
Rand - Yen
Brent Crude
Top 40
All Share
Resource 10
Industrial 25
Financial 15
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.